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Aims It has been suggested that mitochondrial reactive oxygen species (ROS), Akt and Erk1/2 and more recently the
mitochondrial permeability transition pore (mPTP) may act as mediators of ischaemic preconditioning (IPC), although
the actual interplay between these mediators is unclear. The aim of the present study is to determine whether the
cyclophilin-D (CYPD) component of the mPTP is required by IPC to generate mitochondrial ROS and subsequently
activate Akt and Erk1/2.
Methods
and results
Mice lacking CYPD (CYPD2/2) and B6Sv129 wild-type (WT) mice were used throughout. We have demonstrated
that under basal conditions, non-pathological mPTP opening occurs (indicated by the percent reduction in mitochon-
drial calcein ﬂuorescence). This effect was greater in WT cardiomyocytes compared with CYPD2/2 ones (53+2%
WT vs. 17+3% CYPD2/2; P , 0.01) and was augmented by hypoxic preconditioning (HPC) (70+9% WT vs.
56+1% CYPD2/2; P , 0.01). HPC reduced cell death following simulated ischaemia–reperfusion injury in WT
(23.2+3.5% HPC vs. 43.7+3.2% WT; P , 0.05) but not CYPD2/2 cardiomyocytes (19.6+1.4% HPC vs.
24.4+2.6% control; P . 0.05). HPC generated mitochondrial ROS in WT (four-fold increase; P , 0.05) but not
CYPD2/2 cardiomyocytes. HPC induced signiﬁcant Akt phosphorylation in WT cardiomyocytes (two-fold increase;
P , 0.05), an effect which was abrogated by ciclosporin-A (a CYPD inhibitor) and N-2-mercaptopropionyl glycine
(a ROS scavenger). Finally, in vivo IPC of adult murine hearts resulted in signiﬁcant phosphorylation of Akt and
Erk1/2 in WT but not CYPD2/2 hearts.
Conclusion The CYPD component of the mPTP is required by IPC to generate mitochondrial ROS and phosphorylate Akt and
Erk1/2, major steps in the IPC signalling pathway.
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1. Introduction
Mitochondria play a critical role in deciding the fate of cardiomyocytes
subjected to acute ischaemia–reperfusion injury. It is well established
that the mitochondrial dysfunction resulting from the irreversible
pathological opening of the mitochondrial permeability transition
pore (mPTP) at the onset of myocardial reperfusion is a major deter-
minant of cardiomyocyte death following an acute myocardial infarc-
tion.
1,2 The molecular composition of the mPTP remains unclear,
although mitochondrial cyclophilin-D (CYPD) has been reported to
be a critical regulatory component of the mPTP.
3–5 It has been
shown that preventing the pathological form of mPTP opening at
the onset of myocardial reperfusion underlies the infarct-limiting
effects of ischaemic preconditioning (IPC),
6–9 a phenomenon in
which one or more brief episodes of ischaemia and reperfusion
render the myocardium more resistant to a subsequent acute myo-
cardial infarction.
10 The signal transduction pathways recruited by
IPC prior to myocardial ischaemia have been demonstrated to con-
verge on mitochondria resulting in the generation of mitochondrial
reactive oxygen species (ROS), which are released into the cytosol
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Akt, and Erk1/2, critical to IPC protection.
11,12 The mechanism
through which IPC induces mitochondrial ROS production and
whether this ROS is actually responsible for activating these protein
kinases remains to be demonstrated directly.
There is accumulating evidence to suggest that the mPTP can open
reversibly under basal conditions without causing cell death.
13–17 The
signiﬁcance of this form of reversible non-pathological mPTP opening
is unresolved, although previous studies have suggested that it may
contribute to the cardioprotection elicited by IPC via a mechanism
that is not as clear yet.
18,19 In the present study, we sought to deter-
mine whether reversible non-pathological CYPD-dependent mPTP
opening is induced by preconditioning, and whether this form of
mPTP opening is required by IPC to generate mitochondrial ROS,
which in turn are needed to activate the pro-survival protein
kinases, Akt, and Erk1/2, critical mediators of the IPC signalling
pathway.
2. Methods
2.1 Animals
Experiments using animals were carried out in accordance with the
United Kingdom Home Ofﬁce Guide on the Operation of Animal (Scien-
tiﬁc Procedures) Act of 1986. The investigation conforms to the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health. B6Sv129 wild-type (WT) mice were obtained from
Harlan (UK) and cyclophilin-D knockout mice (CYPD2/2) mice were
bred from pairs originally provided by Molkentin’s laboratory.
3,20 WT
and CYPD2/2 male mice (8–10 weeks, 20–30 g) were used throughout
the study.
2.2 Isolating adult murine ventricular
cardiomyocytes
Adult ventricular cardiomyocytes were isolated from WT and CYPD2/2
mice using collagenase digestion according to a previously established
method.
21 The isolated cardiomyocytes were then seeded onto sterilized
laminin-coated coverslips in M199 medium containing 2 g/L BSA, 0.62 g/L
taurine, 0.32 g/L carnitine, 10 units/mL penicillin, 10 mg/L streptomycin,
and 25 mmol/L blebbistatin (Calbiochem, USA) before use on the same
day of isolation.
2.3 Adult murine ventricular cardiomyocyte
model for detecting mPTP opening
To determine whether non-pathological opening of the CYPD-dependent
mPTP occurs under basal conditions and is augmented by hypoxic pre-
conditioning (HPC), a well-established and reproducible technique for
detecting mPTP opening in the isolated adult cardiomyocyte was used
with some modiﬁcations.
15,18,19,22,23 Brieﬂy, freshly isolated cardiomyo-
cytes were loaded with 1.0 mmol/L calcein-AM + 1.0 mmol/L CoCl2 in
order to selectively load the mitochondria with calcein by quenching
the cytosolic calcein signal with CoCl2. The loss of mitochondrial
calcein ﬂuorescence under basal conditions can then be used as a
measure of non-pathological mPTP opening.
15,18,19,22,23
WT and CYPD2/2 cardiomyocytes were randomized to receive
either a standard HPC protocol comprising 10 min simulated ischaemia
followed by 10 min simulated reperfusion or control. Simulated ischaemia
was induced in a custom-made airtight hypoxic chamber using a ischaemic
buffer containing (in mmol/L): 1.0 KH2PO4, 10.0 NaHCO3, 1.2
MgCl2.6H20, 25.0 Na(4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) (HEPES), 74.0 NaCl, 16.0 KCl, 1.2 CaCl2, and 20.0 Na lactate, pH
6.2, bubbled with 95% nitrogen/5% CO2. Simulated reperfusion was
achieved by replacing the buffer with M199 medium containing 2 g/L
BSA, 0.62 g/L taurine, 0.32 g/L carnitine, 10 units/mL penicillin, 10 mg/L
streptomycin. Using a confocal microscope to visualize the cardiomyo-
cytes, the loss of mitochondrial calcein ﬂuorescence was measured over
the course of 30 min in the same cells. The cells were imaged at time
0, 10, and 30 min in order to minimize laser-induced oxidative stress on
the cells. For each time-point, the mean calcein ﬂuorescence was
expressed as a percentage of the initial value. In between imaging, the
cells were returned to the incubator and kept at 37.08C. For the cells
that were randomized to receive HPC, after the baseline images at time
0 had been taken, the cells were placed in an ischaemic buffer and
oxygen was removed by replacing it with nitrogen gas. Following this,
the cells were returned to normoxic buffer (see later) and the same
cells were imaged at 10 and 30 min. For each treatment group, 10 cells
were counted. This experiment was repeated on three separate occasions
giving a total of 30 cells per treatment group.
A Leica confocal microscope (SP5) was used for these experiments. For
the mPTP experiments 1024 × 1024, images of cells were acquired using
low power (2%) 488 nm argon laser (line averaging of 4, zoom 2.2). The
gain was adjusted to achieve maximum signal intensity without saturation.
2.4 Adult murine ventricular cardiomyocyte
model for assessing mitochondrial ROS
production
To determine whether CYPD is required to generate mitochondrial
ROS in response to HPC, WT and CYPD2/2 cardiomyocytes were
loaded with reduced Mitotracker Red CM-H2XRos (Molecular Probes/
Invitrogen) 1.0 mM for 20 min at 37.08C in the incubator and randomized
to the following treatment protocols, following which Mitotracker Red
ﬂuorescence, was measured using a ﬂuorescence microscope in order
to quantify the mitochondrial ROS production: (i) control, DMSO
(0.1%) for 30 min; (ii) HPC, comprising 15 min simulated ischaemia and
15 min simulated reperfusion; (iii) HPC+MPG, HPC in the presence of
the ROS scavenger, N-2-mercaptopropionyl glycine (MPG, 300 mmol/L);
(iv) HPC+CsA, HPC in the presence of CsA (0.4 mmol/L); (v) MPG
alone was given for 30 min; and (vi) CsA alone was given for 30 min.
For each treatment group, at least 25 cells were counted, taken from
three to four randomly selected ﬁelds of view. This experiment was
repeated on three separate occasions giving a total of .75 cells per treat-
ment group.
2.5 Adult murine ventricular cardiomyocyte
model of simulated ischaemia–reperfusion
injury
To determine whether the CYPD is required for cardioprotection elicited
by HPC, WT and CYPD2/2 cardiomyocytes were randomized to the
following treatment protocols prior to subjecting them to simulated
ischaemia–reperfusion injury: (i) control, DMSO (0.1%) for 30 min; (ii)
HPC, comprising 15 min simulated ischaemia and 15 min simulated reper-
fusion; (iii) HPC+MPG, HPC in the presence of the ROS scavenger, MPG
(300 mmol/L); (iv) HPC+CsA, HPC in the presence of CsA (0.4 mmol/L);
(v) MPG alone for 30 min; and (vi) CsA alone for 30 min. The cells were
then subjected to 45 min of simulated ischaemia followed by 30 min of
simulated reperfusion at the end of which cell death was quantiﬁed by
the number of cells staining positive for propidium iodide (3 mmol/L).
For each treatment group, approximately 150 cells were counted. This
experiment was repeated on three separate occasions giving a total of
 450 cells per treatment group.
2.6 Adult murine ventricular cardiomyocyte
model of kinase phosphorylation
To determine whether the HPC-induced phosphorylation of Akt is
mediated by ROS and is dependent on CYPD, WT adult ventricular
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(i) control, containing DMSO (0.1%); (ii) HPC, comprising 15 min simu-
lated ischaemia and 15 min simulated reperfusion; (iii) HPC+MPG, HPC
in the presence of the ROS scavenger, MPG (300 mmol/L); (iv)
HPC+CsA, HPC in the presence of the CYPD inhibitor, CsA
(0.4 mmol/L); (v) MPG alone; (vi) CsA alone; and (vii) insulin (300 units/
L) (this treatment was used as a positive control for Akt phosphorylation),
following which the cardiomyocytes were lysed for subsequent western
blotting analysis for Akt phosphorylation.
2.7 In vivo adult murine model of myocardial
ischaemic preconditioning
To determine whether CYPD is required by IPC to activate Akt and
Erk1/2 in vivo, mice were anesthetized by intraperitoneal injection with a
combination of ketamine, xylazine and atropine (0.01 mL/g, ﬁnal concen-
tration of ketamine, xylazine and atropine were 10, 2, and 0.06 g/L,
respectively) and body temperature was maintained at 37.0+0.58C. A
tracheotomy was performed for artiﬁcial respiration at 120 strokes/min
and 220 mL stroke volume using a rodent Minivent (type 845, Harvard
Apparatus, Kent, UK) and supplemental oxygen was supplied. A limb
lead I electrocardiogram was recorded. A left anterior thoracotomy and
a chest retractor were used to expose the heart. Ligation of the left
anterior descending coronary artery was performed at  2 mm below
the tip of the left atrium using a 8/0 prolene monoﬁlament polypropylene
suture.
21
WT and CYPD2/2 mice were randomized to receive either a stan-
dard IPC protocol or control (n ¼ 4 per treatment group). IPC comprised
of 5 min regional myocardial ischaemia followed by 5 min myocardial
reperfusion following which myocardial tissue taken from the precondi-
tioned myocardium was snap-frozen in liquid nitrogen for subsequent
western blotting analysis. For the control hearts, myocardial tissue was
harvested at an equivalent time-point of the IPC-treated hearts.
2.8 Western blotting analysis for Akt
and Erk1/2
A total of 30 mg of protein (from myocardial tissue) or 30 mL of protein
(from isolated cardiomyocytes) of each sample was loaded into 12.5%
acrylamide gels. The phosphorylation states of Akt (phospho-Akt and
Ser-308) and Erk1/2 (p42/p44) protein levels were determined for each
of the treated groups (n ¼ 4–6 per group). All the antibodies were
obtained from Cell Signalling (Hitchin, Kent) and used in accordance
with the manufacturer’s instructions. Equal protein loading was conﬁrmed
by b-actin (for myocardial tissue) or a-tubulin (for isolated cardio-
myocytes) probing of membranes (Abcam Ltd, UK). Relative densitometry
was determined using a computerized software package NIH Image 1.63.
2.9 Statistical analysis
Values are mean+SEM. Data were analysed using one-way analysis of
variance (ANOVA), followed by Tukey’s multiple comparison post hoc
test. Results from the calcein experiments were analysed by two-way
ANOVA with post-test analysis using Bonferroni correction. P , 0.05
was considered signiﬁcant.
3. Results
3.1 Non-pathological mPTP opening
occurs under basal conditions and is
augmented by hypoxic preconditioning
Over the course of 30 min, there was a signiﬁcant reduction in
mitochondrial calcein ﬂuorescence (expressed as the percentage
reduction of baseline ﬂuorescence) indicating that non-pathological
mPTP opening was occurring under basal conditions. This effect
was greater in WT cardiomyocytes when compared with those
lacking CYPD (53+2% in WT vs. 17+3% in CYPD2/2;
P , 0.01) (Figure 1A and B), indicating that non-pathological mPTP
opening is dependent on CYPD.
Importantly, HPC was demonstrated to induce a further loss of
mitochondrial calcein ﬂuorescence after 30 min which was more
marked in the WT cardiomyocytes when compared with those
lacking CYPD (70+9% in WT vs. 56+1% in CYPD2/2; P ,
0.01) (Figure 1B), indicating that HPC itself can induce non-
pathological mPTP opening over and above that occurring under
basal conditions. Again, this HPC-induced mPTP opening was depen-
dent on CYPD.
Figure 1 (A) Representative confocal images depicting non-
pathological mitochondrial permeability transition pore (mPTP)
opening occurring under basal conditions (as indicated by the redis-
tribution of calcein from the mitochondria into the cytosol), a
phenomenon which occurs to a greater extent in wild-type (WT)
adult murine cardiomyocytes compared with those lacking the
cyclophilin-D component (CYPD2/2) of the mPTP. (B) Non-
pathological mitochondrial permeability transition pore (mPTP)
opening occurred under basal conditions (as indicated by the loss
of mitochondrial calcein ﬂuorescence expressed as a percentage of
the baseline ﬂuorescence), and this phenomenon occurred to a
greater extent in wild-type (WT) adult murine cardiomyocytes com-
pared with those lacking the cyclophilin-D component (CYPD2/2)
component of the mPTP. Hypoxic preconditioning (HPC) augmen-
ted this form of mPTP opening as indicated by a further loss of mito-
chondrial calcein ﬂuorescence, an effect which again occurred to a
greater extent in WT cardiomyocytes compared with those
lacking CYPD. n ¼ 3. *P , 0.05 when compared to WT control.
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preconditioning to generate mitochondrial
ROS
HPC increased the ﬂuorescence of reduced Mitotracker Red in the
mitochondria of WT cardiomyocytes by almost 4-fold (see
Figure 2A for representative ﬂuorescence images) following a standard
HPC protocol (Figure 2B), indicating that HPC induced the production
of mitochondrial ROS. The HPC-induced increase in reduced Mito-
tracker Red ﬂuorescence was abolished in the presence of the
ROS-scavenger, MPG, conﬁrming that the increase in ﬂuorescence
reﬂected mitochondrial ROS production (Figure 2B). Interestingly,
the HPC-induced increase in reduced Mitotracker Red ﬂuorescence
was also abolished in the presence of the CYPD inhibitor, CsA, and
in cardiomyocytes lacking CYPD, HPC failed to increase the ﬂuor-
escence of reduced Mitotracker Red, suggesting that CYPD is
required to generate mitochondrial ROS in response to HPC
(Figure 2B). MPG or CsA when given alone did not inﬂuence
reduced Mitotracker Red ﬂuorescence signiﬁcantly (Figure 2B).
3.3 Protection by hypoxic preconditioning
requires CYPD
A standard HPC protocol reduced cell death following simulated
ischaemia–reperfusion injury in WT cardiomyocytes (23.2+3.5%
with HPC vs. 43.7+3.2% in control; P , 0.05) (Figure 3). This cardi-
oprotective effect of HPC was found to be dependent on ROS, given
that it was abolished in the presence of the ROS scavenger, MPG
(23.2+3.5% with HPC vs. 44.1+2.6% with HPC+MPG; P , 0.05)
(Figure 3), conﬁrming the important mediatory role of ROS in IPC
protection. MPG when given alone had no signiﬁcant effect on cell
death when compared with control (45.5+6.1% with MPG vs.
43.7+3.2% in control; P . 0.05) (Figure 3).
Interestingly, HPC failed to reduce cell death following simulated
ischaemia–simulated reperfusion injury in the presence of CsA in
WT cardiomyocytes (23.2+3.5% with HPC vs. 41.4+2.6% with
HPC+CsA; P , 0.05) and in cardiomyocytes lacking CYPD (19.6+
1.4% with HPC vs. 24.4+2.6% in control; P . 0.05), indicating that
CYPD is required for the cardioprotective effect elicited by HPC
Figure 2 (A) Representative ﬂuorescent images depicting an increase in reduced Mitotracker Red ﬂuorescence (indicating enhanced mitochondrial
ROS production) in WT and CYPD2/2 adult murine cardiomyocytes in control and following a standard hypoxic preconditioning (HPC) protocol.
(B) Hypoxic preconditioning (HPC) induced mitochondrial ROS production (as measured by an increase in reduced Mitotracker Red ﬂuorescence) in
wild-type (WT) cardiomyocytes but not CYPD2/2 cardiomyocytes. This HPC-mediated increase in reduced Mitotracker Red ﬂuorescence was
abrogated in the presence of a ROS scavenger, N-2-mercaptopropionyl glycine (MPG, 300 mM) and mPTP inhibitor, Ciclosporin-A (CsA, 0.4 mM).
Data are normalized to the control WT cardiomyocyte group. n ¼ 3. *P , 0.05 vs. WT control and
#P , 0.05 vs. WT HPC.
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had no signiﬁcant effect on cell death when compared with control in
CYPD2/2 cardiomyocytes (23.8+1.1% with HPC+MPG, 23.9+
1.8% with HPC+CsA, 24.8+1.3% with MPG, and 23.9+1.8%
with CsA vs. 24.4+2.6% in control; P . 0.05) (Figure 3).
3.4 In vivo myocardial ischaemic
preconditioning requires the CYPD
component of the mPTP to phosphorylate
Akt and Erk1/2
Adult murine WT hearts, which were subjected to a standard in vivo
myocardial preconditioning protocol,
20 demonstrated signiﬁcantly
greater phosphorylation of both Akt and Erk1/2 when compared
with control hearts (Figure 4). However, murine hearts lacking
CYPD failed to demonstrate a signiﬁcant increase in Akt or Erk1/2
phosphorylation in response to the IPC stimulus, indicating that
IPC-induced kinase phosphorylation is dependent on CYPD (Figure 4).
3.5 Hypoxic preconditioning requires both
CYPD and ROS to phosphorylate Akt
A standard HPC protocol was found to induce signiﬁcant Akt phos-
phorylation in WT cardiomyocytes (in arbitrary units: 1.60+0.44
with HPC vs. 0.42+0.15 in control; P , 0.05) (Figure 5). This effect
Figure 3 Hypoxic preconditioning (HPC) reduced cell death in
wild-type (WT) cardiomyocytes but not CYPD2/2 cardiomyo-
cytes following simulated ischaemia–reperfusion injury. This protec-
tive effect was abolished in the presence of a ROS scavenger,
N-2-mercaptopropionyl glycine (MPG, 300 mM) and mPTP inhibitor,
Ciclosporin-A (CsA, 0.4 mM). n ¼ 3. *P , 0.05 vs. WT control and
#P , 0.05 vs. WT HPC.
Figure 4 (A) Representative western blot and (B–D) relative densitometries demonstrating that ischaemic preconditioning (IPC) induced the sig-
niﬁcant phosphorylation of both Akt and Erk1/2 (p42/p44) (normalized to b-actin and measured in arbitrary units, au) in wild-type (WT) but not
CYPD2/2 (CYPD) adult murine hearts. n ¼ 4 animals/treatment group. *P , 0.05.
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(1.60+0.44 with HPC vs. 0.50+0.18 with HPC+MPG; P , 0.05)
(Figure 5) and the CYPD inhibitor, CsA (1.60+0.44 with HPC vs.
0.65+0.44 with HPC+CsA; P , 0.05) (Figure 5), indicating that
HPC-induced phosphorylation of Akt is dependent on both CYPD
and ROS. MPG or CsA when given alone had no signiﬁcant effect
on Akt phosphorylation (0.73+0.45 with MPG and 0.41+0.27
with CsA vs. 0.42+0.15 in control; P . 0.05) (Figure 5).
4. Discussion
The salient ﬁndings of the current study are as follows: (i) non-
pathological opening of the mPTP occurs under basal conditions
and this form of mPTP opening is augmented by hypoxic precondi-
tioning (HPC). This form of mPTP opening occurs to a lesser
extent in adult murine cardiomyocytes lacking CYPD; (ii) HPC stimu-
lates mitochondrial ROS production in WT cardiomyocytes but not in
those lacking CYPD, suggesting that the generation of ROS is depen-
dent on the CYPD component of the mPTP; (iii) HPC reduces cell
death following simulated ischaemia–reperfusion injury in WT cardi-
omyocytes but not in those lacking CYPD, suggesting that CypD is the
likely effector of HPC. (iv) HPC induces Akt phosphorylation in WT
cardiomyocytes in a manner which is sensitive to CsA and MPG,
suggesting that both CYPD and ROS are required for HPC-induced
Akt phosphorylation; and (v) in vivo IPC of the adult murine heart
resulted in signiﬁcant phosphorylation of Akt and Erk1/2 in WT
hearts but not in those lacking CYPD, suggesting that the CYP-D
component of the mPTP is required for IPC-induced Akt and Erk1/
2 phosphorylation. These ﬁndings are summarized in a hypothetical
scheme in Figure 6.
In the current study, we took advantage of mice lacking the CYPD
component of the mPTP to demonstrate that the mPTP is required as
a mediator of IPC protection, the generation of mitochondrial ROS
and the subsequent activation of the pro-survival kinases Akt and
Erk1/2.
3–5,20 CYPD is a major regulatory component of the mPTP,
and studies have found that its genetic ablation results in resistance
to calcium-induced mPTP opening,
3,4 a smaller myocardial infarct
size,
3,4 and resistance to the infarct-limiting effects of IPC.
20 Using a
well-established model for detecting mPTP opening in adult ventricu-
lar cardiomyocytes,
15,18,19,22,23 we have demonstrated that under
basal conditions, mPTP opening occurs without causing cell death
and that a standard HPC protocol can actually augment mPTP
opening. Crucially, we have shown that in cardiomyocytes lacking
CYPD, this non-pathological mPTP opening is markedly reduced, pro-
viding conﬁrmatory evidence that the observed reduction in mito-
chondrial calcein ﬂuorescence actually represents mPTP opening.
Figure 5 (A) Representative western blots and (B) relative densi-
tometries demonstrating that hypoxic preconditioning (HPC)
induced the signiﬁcant phosphorylation of Akt (normalized to
a-tubulin and measured in arbitrary units, au) in wild-type (WT) car-
diomyocytes but not in CYPD2/2 cardiomyocytes. This effect was
abrogated in the presence of ciclosporin-A (CsA, a CYPD inhibitor)
and a ROS scavenger, N-2-mercaptopropionyl glycine (MPG,
100 mM). n ¼ 4 animals/treatment group. *P , 0.05.
Figure 6 Hypothetical scheme depicting the potential role for
non-pathological cyclophilin-D (CYPD) dependent mPTP opening
as a mediator of ischaemic preconditioning (IPC) cardioprotection.
We postulate that CYPD is required for the mitochondrial release
of signalling reactive oxygen species (ROS) into the cytosol in
response to an IPC stimulus. The cytosolic signalling ROS then phos-
phorylate and activate critical pro-survival kinases such as Akt and
Erk1/2 which then mediate the inhibition of the pathological form
of CYPD-dependent mPTP opening at the onset of myocardial
reperfusion.
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15 were the ﬁrst to use this cardiomyocyte model for
detecting mPTP opening and they too had observed non-pathological
mPTP opening (termed ‘transient’) occurring in adult rat cardiomyo-
cytes under basal conditions as indicated by the CsA-sensitive loss
of mitochondrial calcein ﬂuorescence.
In the setting of myocardial ischaemia–reperfusion injury, the pre-
vailing paradigm is that the irreversible pathological opening of the
mPTP at the onset of myocardial reperfusion is a critical mediator
of cardiomyocyte death, and preventing its opening at this time can
dramatically reduce myocardial infarct size.
1,2,24 Whether the mPTP
plays any role outside the setting of lethal ischaemia–reperfusion
injury has been controversial, although accumulating data support
the existence of reversible non-pathological mPTP opening occurring
under basal conditions. A number of experimental studies have docu-
mented ‘ﬂickering’ or ‘oscillations’ in mitochondrial membrane poten-
tial that are associated with the production of ROS in isolated
mitochondria and cardiomyocytes, a phenomenon which has been
attributed to reversible opening of the mPTP under basal con-
ditions.
25–28 In contrast, other studies have implicated the opening
of other mitochondrial channels as an explanation of this
phenomenon.
29
A recent experimental study has demonstrated using a variety of
cell types including adult rat cardiomyocytes that stochastic superox-
ide ‘ﬂashes’ occur in individual mitochondria under basal conditions,
and that these are associated with mitochondrial membrane depolar-
ization and mitochondrial calcium efﬂux.
17 Crucially, these superoxide
ﬂashes were found to be reduced both in the presence of pharmaco-
logical inhibitors of mPTP opening (CsA and bongkrekic acid), and in
the presence of siRNA to CYPD,
3,4 suggesting that these superoxide
ﬂashes were the result of non-pathological mPTP opening occurring
under basal conditions. Furthermore, in cardiomyocytes subjected
to simulated ischaemia–reperfusion injury, widespread mitochondrial
superoxide production was associated with the typical pathological
mPTP opening that occurs at the onset of reperfusion.
17
The signiﬁcance of this non-pathological form of mPTP opening is
unclear, but in the current study we report that it is required to gen-
erate ROS, which in turn are needed to activate critical mediators of
IPC-induced cardioprotection. In a previous study, we have reported
that the pharmacological inhibition of mPTP opening using CsA during
a IPC or pharmacological preconditioning protocol abolished the
infarct-limiting effects of IPC, suggesting that some form of non-
pathological mPTP opening was required during the preconditioning
protocol to elicit cardioprotection.
18 In a more recent study,
Saotome et al.
19 have demonstrated that preconditioning with hydro-
gen peroxide could also be blocked by CsA, suggesting that precon-
ditioning with this agent may be upstream of the CYPD-regulated
mPTP. Whether hydrogen peroxide is an upstream activator of the
mPTP in the setting of IPC is unknown.
In the present study, we demonstrate for the ﬁrst time that a stan-
dard HPC protocol augments this form of non-pathological mPTP
opening, a ﬁnding which is compatible with previous studies that
have reported mPTP opening in response to the preconditioning
mimetic, diazoxide.
18,23 It has been established that in response to
an IPC stimulus, mitochondria generate ROS and that this signalling
ROS is required to mediate IPC protection, most probably through
the activation of pro-survival protein kinases such as PKC, PI3K-Akt
and MEK1/2-Erk1/2, although this has not previously been shown
directly.
11 However, the mechanism for the generation of this mito-
chondrial ROS is unresolved and has been attributed by some
studies to the inhibition of mitochondrial respiration and in others
to the opening of the ATP-dependent mitochondrial potassium
channel (mitoKATP channel).
30 In the current study, we provide evi-
dence that the ROS generated by HPC, and observed in WT adult
murine ventricular cardiomyocytes, is dependent on the CYPD com-
ponent of the mPTP, given that cardiomyocytes lacking CYPD failed
to generate mitochondrial ROS in response to HPC. Furthermore,
the phosphorylation of Akt by ROS in response to preconditioning
was also abrogated by CsA, suggesting that CYPD was upstream of
both ROS production and kinase phosphorylation. Whether the
mitoKATP channel acts in conjunction with CypD in generating ROS
in response to the preconditioning stimulus prior to ischaemia is
not clear. However, at myocardial reperfusion and in the context of
inhibiting detrimental lethal mPTP opening, recent studies by Garlid
and co-workers
31 have linked the opening of the mitoKATP channel
to the mPTP inhibition.
The mechanism through which non-pathological mPTP opening
generates ROS is unclear, although a ROS-induced ROS release
coupled with respiratory chain inhibition has been proposed.
17,28 In
this model, any form of mitochondrial stress, such as that induced
by an IPC stimulus, results in partial inhibition of the electron trans-
port chain, which then generates ROS within the mitochondria, trig-
gering non-pathological mPTP opening and resulting in partial
mitochondrial membrane depolarization and further inhibition of
the electron transport chain and so the cycle continues. One can
surmise that under basal conditions, the naturally occurring
ROS-scavenging system keeps the system in check. However, in
response to an IPC stimulus, the ROS generated by the mitochondria
overwhelms the ROS-scavenging capabilities of the mitochondria, the
result of which is ROS entering the cytosol where it activates impor-
tant mediatory kinases implicated in IPC protection.
In this respect, it has been established that the activation of certain
pro-survival kinases such as Akt and Erk1/2 in response to the IPC
protocol is critical to protection.
32 The pharmacological inhibition
of the upstream protein kinases PI3K or MEK1/2 has been reported
to abolish the infarct-limiting effect of IPC, and a recent experimental
study has conﬁrmed that mice lacking PI3K-g are resistant to IPC pro-
tection,
33 conﬁrming the critical role of the PI3K-Akt pathway as a
mediatory protein kinase cascade in IPC. Interestingly, in the
current study, we have shown that IPC did not signiﬁcantly activate
either Akt or Erk1/2 in murine hearts lacking CYPD in vivo, suggesting
that some form of mPTP opening is required to activate these med-
iatory kinases in the setting of IPC. We would speculate that the non-
pathological form of mPTP opening which is accentuated by HPC is
required to generate sufﬁcient mitochondrial ROS which then
enters the cytosol and activates these critical protein kinases. In the
current study, we have directly demonstrated that the Akt phos-
phorylation induced by HPC was dependent on the presence of
CYPD and was mediated by ROS. A previous experimental study
has reported that the preconditioning mimetic diazoxide results in
the activation of Erk1/2 through the mitochondrial generation of
ROS, but in this study mPTP opening was not investigated.
34 There-
fore, the inability to generate ROS in response to a preconditioning
stimulus and the lack of Akt and Erk1/2 phosphorylation with precon-
ditioning may explain the lack of a cardioprotective response to IPC in
mice lacking a CYPD.
20
In summary, we report that the mPTP can reversibly open in adult
cardiomyocytes under basal conditions, and that this form of mPTP
opening is augmented by hypoxic preconditioning. Crucially, the
Cyclophilin-D in ischaemic preconditioning 73CYPD component of the mPTP is critical to IPC protection as it is
required to generate mitochondrial ROS, which in turn activates the
important mediatory protein kinases, Akt, and Erk1/2.
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